Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Grows Position in IQVIA Holdings Inc. $IQV

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 36.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,327 shares of the medical research company’s stock after buying an additional 1,958 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in IQVIA were worth $1,155,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Clal Insurance Enterprises Holdings Ltd raised its stake in IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after acquiring an additional 131 shares during the last quarter. Golden State Wealth Management LLC raised its stake in shares of IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA during the first quarter worth about $33,000. Trust Co. of Toledo NA OH purchased a new stake in IQVIA in the second quarter valued at approximately $39,000. Finally, J.Safra Asset Management Corp increased its holdings in IQVIA by 208.6% in the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after buying an additional 169 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IQV has been the subject of several research reports. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Redburn Partners set a $214.00 target price on shares of IQVIA in a research report on Wednesday, September 3rd. Cowen reaffirmed a “buy” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Mizuho boosted their price objective on IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Finally, Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $234.57.

IQVIA Stock Up 1.0%

Shares of NYSE IQV opened at $220.13 on Friday. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $225.91. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The company’s 50-day simple moving average is $193.88 and its 200-day simple moving average is $170.74. The firm has a market cap of $37.42 billion, a price-to-earnings ratio of 31.86, a price-to-earnings-growth ratio of 2.39 and a beta of 1.32.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period in the previous year, the company posted $2.64 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.